Oramed Pharmaceuticals (NASDAQ:ORMP) Stock: Insider Avraham Gabay Sells 20,000 Shares

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Free Report) CFO Avraham Gabay sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total value of $90,200.00. Following the transaction, the chief financial officer owned 861,076 shares in the company, valued at $3,883,452.76. This trade represents a 2.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oramed Pharmaceuticals Stock Up 0.2%

Shares of NASDAQ:ORMP traded up $0.01 during trading on Friday, hitting $4.49. The stock had a trading volume of 178,322 shares, compared to its average volume of 227,288. The company has a market capitalization of $186.78 million, a PE ratio of 1.09 and a beta of 1.29. The firm’s fifty day moving average is $4.64 and its 200 day moving average is $4.19. Oramed Pharmaceuticals Inc. has a 12 month low of $2.09 and a 12 month high of $5.47.

Get Oramed Pharmaceuticals alerts:

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.52). Equities research analysts expect that Oramed Pharmaceuticals Inc. will post 1.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ORMP. Bank of America Corp DE raised its holdings in Oramed Pharmaceuticals by 2.7% in the first quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company’s stock worth $497,000 after buying an additional 3,909 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Oramed Pharmaceuticals by 5.1% during the first quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock valued at $538,000 after buying an additional 7,738 shares during the last quarter. Engineers Gate Manager LP purchased a new stake in shares of Oramed Pharmaceuticals during the second quarter valued at approximately $61,000. Kathmere Capital Management LLC bought a new stake in shares of Oramed Pharmaceuticals during the first quarter valued at approximately $51,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Oramed Pharmaceuticals during the first quarter valued at approximately $63,000. Institutional investors own 12.73% of the company’s stock.

Wall Street Analyst Weigh In

ORMP has been the topic of a number of research reports. Weiss Ratings restated a “hold (c+)” rating on shares of Oramed Pharmaceuticals in a report on Tuesday, September 8th. Wall Street Zen raised shares of Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Get Our Latest Report on Oramed Pharmaceuticals

About Oramed Pharmaceuticals

(Get Free Report)

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) is a biopharmaceutical company focused on developing orally administered therapies that are traditionally delivered by injection. The company’s technology is designed to protect therapeutic proteins and peptides as they pass through the digestive system and facilitate their absorption in the body.

Oramed’s lead programs have included ORMD-0801, an oral insulin candidate developed for the treatment of diabetes, and ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) analog candidate.

Read More

• Five stocks we like better than Oramed Pharmaceuticals
• AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
• Time to Nibble on MCD Stock After it Enters Oversold Territory?
• McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
• Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.